PCSK9 and endothelial dysfunction: Finally, add-on treatment with PCSK9 inhibitors showed increased plasma levels of miRNAs participating in cholesterol metabolism (miR-122 and miR-27a), endothelial dysfunction (miR-126 and mir-26a), and inflammation (miR-92a, miR-155, and miR-125a).